Homocysteine, B vitamins, and cardiovascular disease [7]

New England Journal of Medicine

Volumn 355, Issue 2, 2006, Pages 207-

  Refsum, Helga ^a   Smith, A David ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; VITAMIN B GROUP; VITAMIN B COMPLEX;

CANADA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CYANOCOBALAMIN DEFICIENCY; DRUG BLOOD LEVEL; FOOD INTAKE; HUMAN; HYPERHOMOCYSTEINEMIA; ISCHEMIC HEART DISEASE; LETTER; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; STROKE; SYSTEMATIC REVIEW; UNITED STATES; VITAMIN SUPPLEMENTATION; CARDIOVASCULAR DISEASE; NOTE; STATISTICAL ANALYSIS;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; FOLIC ACID; HUMANS; HYPERHOMOCYSTEINEMIA; VITAMIN B 12; VITAMIN B 6; VITAMIN B COMPLEX;

EID: 33745918660     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202-6.
2. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
3. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75.
4. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin Intervention for Stroke Prevention trial: an efficacy analysis. Stroke 2005;36:2404-9.
5. Yang Q, Botto LD, Erickson JD, et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 2006;113:1335-43.